Literature DB >> 28944213

Comment on "Predictors of short-term outcomes related to central subfield foveal thickness after intravitreal bevacizumab for macular edema due to central retinal vein occlusion".

Dan Călugăru1, Mihai Călugăru1.   

Abstract

Entities:  

Year:  2017        PMID： 28944213      PMCID： PMC5596239          DOI： 10.18240/ijo.2017.09.25

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN： 2222-3959            Impact factor:   1.779


× No keyword cloud information.
  7 in total

1.  Letter to the Editor: Treat-and-Extend Intravitreal Bevacizumab for Branch Retinal Vein Occlusion.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2015 Nov-Dec       Impact factor: 1.300

2.  Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2015-03       Impact factor: 5.258

3.  OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlusion.

Authors:  Alexandra Eva Hoeh; Mira Ruppenstein; Thomas Ach; Stefan Dithmar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-07-02       Impact factor: 3.117

4.  Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  J Ocul Pharmacol Ther       Date:  2014-10-14       Impact factor: 2.671

5.  Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase.

Authors:  S S Hayreh; M R Klugman; M Beri; A E Kimura; P Podhajsky
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

6.  Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion.

Authors:  Eun Jee Chung; Young Taek Hong; Sung Chul Lee; Oh Woong Kwon; Hyoung Jun Koh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-06-11       Impact factor: 3.117

7.  Predictors of short-term outcomes related to central subfield foveal thickness after intravitreal bevacizumab for macular edema due to central retinal vein occlusion.

Authors:  Mei-Zi Wang; Kang Feng; Yao Lu; Fang Qian; Xin-Rong Lu; Si-Wen Zang; Lin Zhao
Journal:  Int J Ophthalmol       Date:  2016-01-18       Impact factor: 1.779
  7 in total
  1 in total

1.  Safety and long-term efficacy of repeated dexamethasone intravitreal implant for the treatment of cystoid macular edema secondary to retinal vein occlusion with and without a switch to anti-VEGF agents: a 3-year experience.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-02       Impact factor: 3.117
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.